Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

884
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
884
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

692
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
692
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

295
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
295
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

293
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
293
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

469
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
469

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Leptospiral uveitis: A late complication of systemic leptospirosis.

The Indian journal of medical research·2026
Same author

Fusicolla species as a rare cause of fungal endophthalmitis: A case report.

Diagnostic microbiology and infectious disease·2026
Same author

Trematode induced ocular granuloma in children from South India.

Indian journal of ophthalmology·2026
Same author

Emerging trends in parasitic uveitis due to Gnathostoma spinigerum: A case series and diagnostic challenge.

Indian journal of ophthalmology·2025
Same author

Geographic helicoid peripapillary choroidopathy: a photo essay.

Eye (London, England)·2024
Same author

Outer retinal deposits as initial manifestation of occipital B cell lymphoma: photo essay.

Eye (London, England)·2024

Related Experiment Video

Updated: Mar 13, 2026

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

3.3K

Noninfectious uveitis: Management with biologic agents.

S R Rathinam1, Somanath Anjana

  • 1Uveitis Service, Aravind Eye Hospital and PG Institute of Ophthalmology, Madurai, Tamil Nadu, India.

Indian Journal of Ophthalmology
|March 12, 2026
PubMed
Summary

Biologic agents, such as anti-tumor necrosis factor alpha (TNF-α) therapies, offer effective treatment for noninfectious uveitis when corticosteroids fail. These advanced therapies help manage inflammation and prevent vision loss in patients with refractory cases.

Keywords:
AdalimumabJanus kinase inhibitorsRituximabbiologicsnoninfectious uveitis

More Related Videos

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

6.3K
Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

1.1K

Related Experiment Videos

Last Updated: Mar 13, 2026

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

3.3K
Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

6.3K
Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

1.1K

Area of Science:

  • Ophthalmology
  • Immunology
  • Pharmacology

Background:

  • Uveitis is a significant cause of vision loss, involving inflammation of the eye's middle layer.
  • Corticosteroids are the primary treatment for noninfectious uveitis, but alternatives are needed for refractory cases.

Purpose of the Study:

  • To review the role and effectiveness of biologic agents in managing noninfectious uveitis.
  • To highlight emerging biologic therapies for uveitis treatment.

Main Methods:

  • Literature review of studies on biologic agents for noninfectious uveitis.
  • Analysis of clinical trial data and case reports on anti-TNF-α agents and other biologics.

Main Results:

  • Anti-tumor necrosis factor alpha (TNF-α) agents, like adalimumab, are effective in treating noninfectious uveitis.
  • Other biologics, including interleukin and Janus kinase inhibitors, show promise for uveitis management.

Conclusions:

  • Biologic agents are valuable alternatives for patients with noninfectious uveitis intolerant to or refractory to conventional therapies.
  • Further research is needed to confirm the long-term safety and efficacy of biologic treatments for uveitis.